Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 7 (July)

1. Symptomatic metastases to the pituitary infundibulum resulting from primary breast cancer.
   Int J Clin Oncol, 10(3): 191-4. [Abstract] [Full-text]
2. Intensity-modulated radiotherapy technique for three-field breast treatment.
   Int J Radiat Oncol Biol Phys, 62(4): 1217-23. [Abstract] [Full-text]
3. The patterns of care study for breast-conserving therapy in Japan: analysis of process survey from 1995 to 1997.
   Int J Radiat Oncol Biol Phys, 62(4): 1048-54. [Abstract] [Full-text]
4. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT).
   Int J Radiat Oncol Biol Phys, 62(4): 1040-7. [Abstract] [Full-text]
5. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation.
   Int J Radiat Oncol Biol Phys, 62(4): 1035-9. [Abstract] [Full-text]
6. Selective insensitivity of ZR-75-1 human breast cancer cells to 2-methoxyestradiol: evidence for type II 17beta-hydroxysteroid dehydrogenase as the underlying cause.
   Cancer Res, 65(13): 5802-11. [Abstract] [Full-text]
7. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment.
   Cancer Res, 65(13): 5785-91. [Abstract] [Full-text]
8. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.
   Cancer Res, 65(13): 5778-84. [Abstract] [Full-text]
9. The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer.
   Cancer Res, 65(13): 5696-702. [Abstract] [Full-text]
10. Lack of telopeptides in fibrillar collagen I promotes the invasion of a metastatic breast tumor cell line.
    Cancer Res, 65(13): 5674-82. [Abstract] [Full-text]
11. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue.
    Cancer Res, 65(13): 5599-606. [Abstract] [Full-text]
12. Using a xenograft model of human breast cancer metastasis to find genes associated with clinically aggressive disease.
    Cancer Res, 65(13): 5578-87. [Abstract] [Full-text]
13. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.
    Cancer Res, 65(13): 5506-11. [Abstract] [Full-text]
14. Persistence of medical change at implementation of clinical guidelines on medical practice: a controlled study in a cancer network.
    J Clin Oncol, 23(19): 4414-23. [Abstract] [Full-text]
15. Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy.
    J Clin Oncol, 23(19): 4399-405. [Abstract] [Full-text]
16. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial.
    J Clin Oncol, 23(19): 4312-21. [Abstract] [Full-text]
17. Interventions to enhance physical and psychological functioning among younger women who are ending nonhormonal adjuvant treatment for early-stage breast cancer.
    J Clin Oncol, 23(19): 4298-311. [Abstract] [Full-text]
18. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    J Clin Oncol, 23(19): 4287-97. [Abstract] [Full-text]
19. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin.
    Free Radic Biol Med, 39(3): 403-11. [Abstract] [Full-text]
20. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis.
    Cancer Genet Cytogenet, 160(2): 164-8. [Abstract] [Full-text]
21. An intronic variant in the TP53 gene in a Brazilian woman with breast cancer.
    Cancer Genet Cytogenet, 160(2): 160-3. [Abstract] [Full-text]
22. Genetic losses in breast cancer: toward an integrated molecular cytogenetic map.
    Cancer Genet Cytogenet, 160(2): 141-51. [Abstract] [Full-text]
23. Complex CGH alterations on chromosome arm 8p at candidate tumor suppressor gene loci in breast cancer cell lines.
    Cancer Genet Cytogenet, 160(2): 134-40. [Abstract] [Full-text]
24. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited.
    Am J Epidemiol, 162(2): 165-70. [Abstract] [Full-text]
25. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
    J Clin Oncol, 23(19): 4265-74. [Abstract] [Full-text]
26. Analysis of the DNA substrate specificity of the human BACH1 helicase associated with breast cancer.
    J Biol Chem, 280(27): 25450-60. [Abstract] [Full-text]
27. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.
    J Clin Oncol, 23(19): 4347-53. [Abstract] [Full-text]
28. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project.
    J Clin Oncol, 23(19): 4275-86. [Abstract] [Full-text]
29. Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry.
    Proteomics, 5(10): 2680-8. [Abstract] [Full-text]
30. Association of TNF-alpha and TNF-beta gene polymorphism with steroid receptor expression in breast cancer patients.
    Pathol Oncol Res, 11(2): 99-102. [Abstract] [Full-text]
31. Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma.
    Pathol Oncol Res, 11(2): 92-7. [Abstract] [Full-text]
32. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute.
    J Natl Cancer Inst, 97(13): 966-75. [Abstract] [Full-text]
33. Concordant loss of fragile gene expression early in breast cancer development.
    Pathol Int, 55(8): 471-8. [Abstract] [Full-text]
34. New directions for critical internet health studies: representing cancer experience on the web.
    Sociol Health Illn, 27(4): 515-40. [Abstract] [Full-text]
35. HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.
    Br J Cancer, 93(1): 7-14. [Abstract] [Full-text]
36. No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype.
    Br J Cancer, 93(1): 167-71. [Abstract] [Full-text]
37. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
    Cancer, 104(2): 257-63. [Abstract] [Full-text]
38. Influence of the time between surgery and radiotherapy on local recurrence in patients with lymph node-positive, early-stage, invasive breast carcinoma undergoing breast-conserving surgery: results of the French Adjuvant Study Group.
    Cancer, 104(2): 240-50. [Abstract] [Full-text]
39. Soybean products and reduction of breast cancer risk: a case-control study in Japan.
    Br J Cancer, 93(1): 15-22. [Abstract] [Full-text]
40. Barriers to minority participation in breast carcinoma prevention trials.
    Cancer, 104(2): 374-9. [Abstract] [Full-text]
41. The melanoma antigen gene as a surveillance marker for the detection of circulating tumor cells in patients with breast carcinoma.
    Cancer, 104(2): 251-6. [Abstract] [Full-text]
42. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
    Cancer, 104(2): 229-35. [Abstract] [Full-text]
43. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
    Cancer, 104(2): 236-9. [Abstract] [Full-text]
44. Exposure to the electrofusion process can increase the immunogenicity of human cells.
    Cancer Immunol Immunother, 54(9): 880-90. [Abstract] [Full-text]
45. Tissue tonometry before and after liposuction of arm lymphedema following breast cancer.
    Lymphat Res Biol, 3(2): 66-80. [Abstract] [Full-text]
46. Aberrant hypermethylation of ID4 gene promoter region increases risk of lymph node metastasis in T1 breast cancer.
    Oncogene, 24(29): 4721-7. [Abstract] [Full-text]
47. Identification of molecular apocrine breast tumours by microarray analysis.
    Oncogene, 24(29): 4660-71. [Abstract] [Full-text]
48. HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma.
    Oncogene, 24(29): 4609-23. [Abstract] [Full-text]
49. Factors predicting failure to identify a sentinel lymph node in breast cancer.
    Surgery, 138(1): 56-63. [Abstract] [Full-text]
50. Hydantoin derivative formation from oxidation of 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxodG) and incorporation of 14C-labeled 8-oxodG into the DNA of human breast cancer cells.
    Bioorg Med Chem Lett, 15(15): 3627-31. [Abstract] [Full-text]
51. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer.
    Clin Chem Lab Med, 43(6): 617-27. [Abstract] [Full-text]
52. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters.
    Exp Mol Pathol, 79(1): 42-50. [Abstract] [Full-text]
53. Multidetector row computed tomography for diagnosing intraductal extension of breast carcinoma.
    J Surg Oncol, 91(1): 10-6. [Abstract] [Full-text]
54. Rapid mutation detection in complex genes by heteroduplex analysis with capillary array electrophoresis.
    Electrophoresis, 26(13): 2539-52. [Abstract] [Full-text]
55. Breast cancer survivors involved in vigorous team physical activity: psychosocial correlates of maintenance participation.
    Psychooncology, 14(7): 594-605. [Abstract] [Full-text]
56. Surgeon's recommendation, perceived operative efficacy and age dictate treatment choice by Chinese women facing breast cancer surgery.
    Psychooncology, 14(7): 585-93. [Abstract] [Full-text]
57. The validity of the family relationships index as a screening tool for psychological risk in families of cancer patients.
    Psychooncology, 14(7): 546-54. [Abstract] [Full-text]
58. Psychological distress among healthy women with family histories of breast cancer: effects of recent life events.
    Psychooncology, 14(7): 555-63. [Abstract] [Full-text]
59. Depression experienced by young women newly diagnosed with breast cancer.
    Psychooncology, 14(7): 564-73. [Abstract] [Full-text]
60. Mental health outcomes in older women with breast cancer: impact of perceived family support and adjustment.
    Psychooncology, 14(7): 535-45. [Abstract] [Full-text]
61. Determinants of the demand for breast cancer screening among women veterans in the United States.
    Soc Sci Med, 61(7): 1608-17. [Abstract] [Full-text]
62. ETV6 gene rearrangements in invasive breast carcinoma.
    Genes Chromosomes Cancer, 44(1): 103-8. [Abstract] [Full-text]
63. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?
    J Pathol, 206(4): 451-7. [Abstract] [Full-text]
64. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.
    Hum Pathol, 36(6): 634-9. [Abstract] [Full-text]
65. Taking the transtheoretical model into the field: a curriculum for lay health advisors.
    Health Promot Pract, 6(3): 329-37. [Abstract] [Full-text]
66. Social support as a mediator between symptom distress and quality of life in women with breast cancer.
    J Obstet Gynecol Neonatal Nurs, 34(4): 482-93. [Abstract] [Full-text]
67. Access to breast cancer screening services for women with disabilities.
    J Obstet Gynecol Neonatal Nurs, 34(4): 453-64. [Abstract] [Full-text]
68. Simultaneous reconstruction of breast and well-projected nipple after expansion of mammary skin.
    Scand J Plast Reconstr Surg Hand Surg, 39(2): 77-84. [Abstract] [Full-text]
69. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer.
    Gynecol Endocrinol, 20(6): 343-60. [Abstract] [Full-text]
70. Pituitary adenylate cyclase-activating peptide/vasoactive intestinal peptide receptors in human normal mammary gland and breast cancer tissue.
    Gynecol Endocrinol, 20(6): 327-33. [Abstract] [Full-text]
71. Polycystic ovary syndrome and gynecological cancers: is there a link?
    Gynecol Endocrinol, 20(4): 200-8. [Abstract] [Full-text]
72. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells.
    FEBS Lett, 579(18): 3932-40. [Abstract] [Full-text]
73. STAT1 and Nmi are downstream targets of Ets-1 transcription factor in MCF-7 human breast cancer cell.
    FEBS Lett, 579(18): 3941-6. [Abstract] [Full-text]
74. Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen.
    Histochem Cell Biol, 123(6): 631-7. [Abstract] [Full-text]
75. The relationship between blood leptin level and bone density is specific to ethnicity and menopausal status.
    J Lab Clin Med, 146(1): 18-24. [Abstract] [Full-text]
76. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
    Cancer Res, 65(14): 6371-9. [Abstract] [Full-text]
77. Tomographic fluorescence mapping of tumor targets.
    Cancer Res, 65(14): 6330-6. [Abstract] [Full-text]
78. The novel gene EG-1 stimulates cellular proliferation.
    Cancer Res, 65(14): 6159-66. [Abstract] [Full-text]
79. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer.
    Cancer Res, 65(14): 6139-50. [Abstract] [Full-text]
80. A mouse model of human breast cancer metastasis to human bone.
    Cancer Res, 65(14): 6130-8. [Abstract] [Full-text]
81. Epidermal growth factor-induced signaling in breast cancer cells results in selective target gene activation by orphan nuclear receptor estrogen-related receptor alpha.
    Cancer Res, 65(14): 6120-9. [Abstract] [Full-text]
82. Rho GDP dissociation inhibitor protects cancer cells against drug-induced apoptosis.
    Cancer Res, 65(14): 6054-62. [Abstract] [Full-text]
83. The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells.
    Cancer Res, 65(14): 6042-53. [Abstract] [Full-text]
84. Guidelines to assure quality in breast cancer surgery.
    Eur J Surg Oncol, 31(6): 568-76. [Abstract] [Full-text]
85. Breast surgery as a specialized practice.
    Am J Surg, 190(2): 264-8. [Abstract] [Full-text]
86. Image-guided breast surgery.
    Am J Surg, 190(2): 221-7. [Abstract] [Full-text]
87. Body size changes in relation to postmenopausal breast cancer among women on Long Island, New York.
    Am J Epidemiol, 162(3): 229-37. [Abstract] [Full-text]
88. Significance of inducible nitric oxide synthase expression in benign and malignant breast epithelium: an immunohistochemical study of 151 cases.
    Virchows Arch, 447(1): 24-30. [Abstract] [Full-text]
89. Quality control in breast cancer surgery.
    Eur J Surg Oncol, 31(6): 577-86. [Abstract] [Full-text]
90. A longitudinal prospective study of health-related quality of life in breast cancer patients following high-dose chemotherapy with autologous blood stem cell transplantation.
    Bone Marrow Transplant, 36(3): 251-9. [Abstract] [Full-text]
91. DCIS, cytokeratins, and the theory of the sick lobe.
    Virchows Arch, 447(1): 1-8. [Abstract] [Full-text]
92. Expression profiling of ABC transporters in a drug-resistant breast cancer cell line using AmpArray.
    Mol Pharmacol, 68(2): 430-8. [Abstract] [Full-text]
93. DNA damage uncouples the mitogenic response to IGF-I in MCF-7 malignant breast cancer cells by switching the roles of PI3 kinase and p21WAF1/Cip1.
    Int J Cancer, 116(4): 506-13. [Abstract] [Full-text]
94. Complementary role of adjunctive breast magnetic resonance imaging and scintimammography in patients of all ages undergoing breast cancer surgery.
    Australas Radiol, 49(4): 289-97. [Abstract] [Full-text]
95. Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer.
    Eur J Cancer, 41(11): 1515-27. [Abstract] [Full-text]
96. Hereditary breast cancer growth rates and its impact on screening policy.
    Eur J Cancer, 41(11): 1610-7. [Abstract] [Full-text]
97. Tuberin and hamartin are aberrantly expressed and linked to clinical outcome in human breast cancer: the role of promoter methylation of TSC genes.
    Eur J Cancer, 41(11): 1628-36. [Abstract] [Full-text]
98. Structural and functional analyses of a novel ig-like cell adhesion molecule, hepaCAM, in the human breast carcinoma MCF7 cells.
    J Biol Chem, 280(29): 27366-74. [Abstract] [Full-text]
99. StarD10, a START domain protein overexpressed in breast cancer, functions as a phospholipid transfer protein.
    J Biol Chem, 280(29): 27436-42. [Abstract] [Full-text]
100. Antisense-mediated Inhibition of the plasma membrane calcium-ATPase suppresses proliferation of MCF-7 cells.
     J Biol Chem, 280(29): 27076-84. [Abstract] [Full-text]
101. Smad4 inhibits tumor growth by inducing apoptosis in estrogen receptor-alpha-positive breast cancer cells.
     J Biol Chem, 280(29): 27022-8. [Abstract] [Full-text]
102. Analyser-based mammography using single-image reconstruction.
     Phys Med Biol, 50(15): 3599-611. [Abstract] [Full-text]
103. Evaluation of dose-response models and parameters predicting radiation induced pneumonitis using clinical data from breast cancer radiotherapy.
     Phys Med Biol, 50(15): 3535-54. [Abstract] [Full-text]
104. Scanning path optimization for ultrasound surgery.
     Phys Med Biol, 50(15): 3473-90. [Abstract] [Full-text]
105. Urinary melatonin levels and breast cancer risk.
     J Natl Cancer Inst, 97(14): 1084-7. [Abstract] [Full-text]
106. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants.
     J Natl Cancer Inst, 97(14): 1080-3. [Abstract] [Full-text]
107. Efficacy of breast cancer screening in the community according to risk level.
     J Natl Cancer Inst, 97(14): 1035-43. [Abstract] [Full-text]
108. Common polymorphisms in ERCC2 (Xeroderma pigmentosum D) are not associated with breast cancer risk.
     Cancer Epidemiol Biomarkers Prev, 14(7): 1828-31. [Abstract] [Full-text]
109. Obesity and outcomes in premenopausal and postmenopausal breast cancer.
     Cancer Epidemiol Biomarkers Prev, 14(7): 1686-91. [Abstract] [Full-text]
110. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
     Cancer Epidemiol Biomarkers Prev, 14(7): 1681-5. [Abstract] [Full-text]
111. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins.
     Cancer Epidemiol Biomarkers Prev, 14(7): 1672-80. [Abstract] [Full-text]
112. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families.
     Cancer Epidemiol Biomarkers Prev, 14(7): 1666-71. [Abstract] [Full-text]
113. Vitamin D and calcium intakes from food or supplements and mammographic breast density.
     Cancer Epidemiol Biomarkers Prev, 14(7): 1653-9. [Abstract] [Full-text]
114. TLD skin dose measurements and acute and late effects after lumpectomy and high-dose-rate brachytherapy only for early breast cancer.
     Int J Radiat Oncol Biol Phys, 62(5): 1283-90. [Abstract] [Full-text]
115. A cosmetic evaluation of breast cancer treatment: a randomized study of radiotherapy boost technique.
     Int J Radiat Oncol Biol Phys, 62(5): 1274-82. [Abstract] [Full-text]
116. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
     Br J Cancer, 93(2): 173-7. [Abstract] [Full-text]
117. Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia.
     Br J Cancer, 93(2): 260-5. [Abstract] [Full-text]
118. Anastrozole.
     Drugs Today (Barc), 41(4): 227-39. [Abstract] [Full-text]
119. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
     J Clin Oncol, 23(21): 4695-704. [Abstract] [Full-text]
120. Benign breast disease and the risk of breast cancer.
     N Engl J Med, 353(3): 229-37. [Abstract] [Full-text]
121. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index.
     Mod Pathol, 18(8): 1067-78. [Abstract] [Full-text]
122. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations.
     Mod Pathol, 18(8): 1027-33. [Abstract] [Full-text]
123. Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.
     Mod Pathol, 18(8): 1015-21. [Abstract] [Full-text]
124. Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry.
     J Clin Oncol, 23(21): 4679-86. [Abstract] [Full-text]
125. The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore.
     Carcinogenesis, 26(8): 1457-64. [Abstract] [Full-text]
126. Gene expression profiling of NMU-induced rat mammary tumors: cross species comparison with human breast cancer.
     Carcinogenesis, 26(8): 1343-53. [Abstract] [Full-text]
127. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
     J Clin Oncol, 23(21): 4687-94. [Abstract] [Full-text]
128. Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore.
     Carcinogenesis, 26(8): 1389-94. [Abstract] [Full-text]
129. Mammotome: less invasive than ABBI with similar accuracy for early breast cancer detection.
     World J Surg, 29(4): 495-9. [Abstract] [Full-text]
130. Hepatic resection for metastatic breast cancer: prognostic analysis of 34 patients.
     World J Surg, 29(4): 524-7. [Abstract] [Full-text]
131. The safety and accuracy of sentinel-node biopsy in early-stage invasive breast cancer--Turkish experience.
     J Invest Surg, 18(3): 129-34. [Abstract] [Full-text]
132. Malignant phyllodes tumor of the prostate.
     Arch Androl, 51(4): 295-8. [Abstract] [Full-text]
133. Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling.
     Oncogene, 24(31): 4908-20. [Abstract] [Full-text]
134. Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T.
     Radiology, 236(2): 465-75. [Abstract] [Full-text]
135. Solid breast masses: classification with computer-aided analysis of continuous US images obtained with probe compression.
     Radiology, 236(2): 458-64. [Abstract] [Full-text]
136. Computer-aided detection with screening mammography in a university hospital setting.
     Radiology, 236(2): 451-7. [Abstract] [Full-text]
137. Impairments, activity limitations and participation restrictions 6 and 12 months after breast cancer operation.
     J Rehabil Med, 37(3): 180-8. [Abstract] [Full-text]
138. Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility.
     Cytotherapy, 7(1): 46-56. [Abstract] [Full-text]
139. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining.
     Am J Clin Pathol, 124(2): 273-81. [Abstract] [Full-text]
140. Approaches to managing bone metastases from breast cancer: the role of bisphosphonates.
     Cancer Treat Rev, 31(4): 303-11. [Abstract] [Full-text]
141. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.
     Mol Cell, 19(2): 159-70. [Abstract] [Full-text]
142. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer.
     Lancet, 366(9482): 318-20. [Abstract] [Full-text]
143. Accuracy of intraoperative frozen-section analysis of breast cancer lumpectomy-bed margins.
     J Am Coll Surg, 201(2): 194-8. [Abstract] [Full-text]
144. Radio-guided localization of clinically occult breast lesions (ROLL): a DGH experience.
     Clin Radiol, 60(6): 681-6. [Abstract] [Full-text]
145. The effect of changing from one to two views at incident (subsequent) screens in the NHS breast screening programme in England: impact on cancer detection and recall rates.
     Clin Radiol, 60(6): 674-80. [Abstract] [Full-text]
146. Is radiologists' volume of mammography reading related to accuracy? A critical review of the literature.
     Clin Radiol, 60(6): 623-6. [Abstract] [Full-text]
147. Development of a self-efficacy scale for mammography.
     Res Nurs Health, 28(4): 329-36. [Abstract] [Full-text]
148. Oestrogenic activity of p-hydroxybenzoic acid (common metabolite of paraben esters) and methylparaben in human breast cancer cell lines.
     J Appl Toxicol, 25(4): 301-9. [Abstract] [Full-text]
149. Central nervous system metastases in breast cancer patients administered trastuzumab.
     Cancer Treat Rev, 31(4): 312-8. [Abstract] [Full-text]
150. Professional and economic factors affecting access to mammography: a crisis today, or tomorrow? Results from a national survey.
     Cancer, 104(3): 491-8. [Abstract] [Full-text]
151. Psychologic and social sequelae of secondary lymphedema: a review.
     Cancer, 104(3): 457-66. [Abstract] [Full-text]
152. The clinical use of staging bone scan in patients with breast carcinoma: reevaluation by the 2003 American Joint Committee on Cancer staging system.
     Cancer, 104(3): 499-503. [Abstract] [Full-text]
153. Clinical management of osteoporosis in women with a history of breast carcinoma.
     Cancer, 104(3): 443-56. [Abstract] [Full-text]
154. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
     Cancer, 104(3): 479-90. [Abstract] [Full-text]
155. The use of a panel of monoclonal antibodies to enrich circulating breast cancer cells facilitates their detection.
     Gynecol Oncol, 98(2): 211-6. [Abstract] [Full-text]
156. American College of Radiology Imaging Network digital mammographic imaging screening trial: objectives and methodology.
     Radiology, 236(2): 404-12. [Abstract] [Full-text]
157. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review.
     Cancer Treat Rev, 31(4): 283-302. [Abstract] [Full-text]
158. A comparison of fulvestrant and the third-generation aromatase inhibitors in the second-line treatment of postmenopausal women with advanced breast cancer.
     Cancer Treat Rev, 31(4): 274-82. [Abstract] [Full-text]
159. Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.
     Mol Carcinog, 43(4): 225-36. [Abstract] [Full-text]
160. Limited English proficiency and breast and cervical cancer screening in a multiethnic population.
     Am J Public Health, 95(8): 1410-6. [Abstract] [Full-text]
161. The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenograftsis attributed to both its lignan and oil components.
     Int J Cancer, 116(5): 793-8. [Abstract] [Full-text]
162. Potential anticancer activity of tanshinone IIA against human breast cancer.
     Int J Cancer, 116(5): 799-807. [Abstract] [Full-text]
163. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients.
     Int J Cancer, 116(5): 734-9. [Abstract] [Full-text]
164. Prospective study of alcohol consumption and breast cancer risk in Japanese women.
     Int J Cancer, 116(5): 779-83. [Abstract] [Full-text]
165. Invasive breast cancer following ductal and lobular carcinoma in situ of the breast.
     Int J Cancer, 116(5): 820-3. [Abstract] [Full-text]
166. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo.
     Int J Cancer, 116(5): 686-91. [Abstract] [Full-text]
167. Transfection of keratin 18 gene in human breast cancer cells causes induction of adhesion proteins and dramatic regression of malignancy in vitro and in vivo.
     Mol Cancer Res, 3(7): 365-71. [Abstract] [Full-text]
168. Short communication: Setup variations in locoregional radiotherapy for breast cancer: an electronic portal imaging study.
     Br J Radiol, 78(932): 742-5. [Abstract] [Full-text]
169. Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63.
     Histopathology, 47(2): 202-8. [Abstract] [Full-text]
170. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
     Histopathology, 47(2): 195-201. [Abstract] [Full-text]
171. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
     Cancer Chemother Pharmacol, 56(4): 361-9. [Abstract] [Full-text]
172. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
     Cancer Chemother Pharmacol, 56(4): 370-8. [Abstract] [Full-text]
173. Genes that mediate breast cancer metastasis to lung.
     Nature, 436(7050): 518-24. [Abstract] [Full-text]
174. Comparison of liquid based cytology and histology for the evaluation of HER-2 status using immunostaining and CISH in breast carcinoma.
     J Clin Pathol, 58(8): 864-71. [Abstract] [Full-text]
175. Distinct epigenetic changes in the stromal cells of breast cancers.
     Nat Genet, 37(8): 899-905. [Abstract] [Full-text]
176. Integrin alpha6beta4 promotes expression of autotaxin/ENPP2 autocrine motility factor in breast carcinoma cells.
     Oncogene, 24(32): 5125-30. [Abstract] [Full-text]
177. Assessing the benefit of radiation therapy after breast-conserving surgery for ductal carcinoma-in-situ.
     J Clin Oncol, 23(22): 5171-7. [Abstract] [Full-text]
178. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
     J Clin Oncol, 23(22): 5166-70. [Abstract] [Full-text]
179. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer.
     J Clin Oncol, 23(22): 5155-65. [Abstract] [Full-text]
180. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer.
     J Clin Oncol, 23(22): 5148-54. [Abstract] [Full-text]
181. Persistence of restrictions in quality of life from the first to the third year after diagnosis in women with breast cancer.
     J Clin Oncol, 23(22): 4945-53. [Abstract] [Full-text]
182. BRCA1 in breast and ovarian cancer predisposition.
     Cancer Lett, 227(1): 1-7. [Abstract] [Full-text]
183. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
     J Clin Oncol, 23(22): 5138-47. [Abstract] [Full-text]
184. Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.
     J Clin Oncol, 23(22): 5178-87. [Abstract] [Full-text]
185. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
     J Clin Oncol, 23(22): 5108-16. [Abstract] [Full-text]
186. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
     J Clin Oncol, 23(22): 5126-37. [Abstract] [Full-text]
187. Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients.
     J Clin Oncol, 23(22): 5117-25. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.